Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106751 | 0.94 | TSHR (0.43) | TSHREPHX2P2RX7LMNAMAPK1 | |
| SCHEMBL5110169 | 0.87 | EPHX2 (0.48) | TSHREPHX2P2RX7LMNAMAPK1 | |
| SCHEMBL5110205 | 0.82 | TSHR (0.44) | TSHREPHX2P2RX7LMNAMAPK1 | |
| SCHEMBL5121631 | 0.81 | PPARG (0.48) | TSHREPHX2P2RX7LMNAMAPK1 | |
| SCHEMBL5109316 | 0.80 | P2RX3 (0.41) | EPHX2P2RX7PPARG | |
| SCHEMBL5120428 | 0.79 | PPARG (0.58) | TSHREPHX2P2RX7PPARGRECQL | |
| SCHEMBL5115472 | 0.79 | PPARG (0.59) | TSHREPHX2P2RX7PPARGRECQL | |
| SCHEMBL5113109 | 0.79 | PPARG (0.51) | TSHREPHX2P2RX7LMNAPPARG | |
| SCHEMBL5113332 | 0.77 | EPHX2 (0.48) | TSHREPHX2P2RX7LMNAMAPK1 | |
| SCHEMBL5109820 | 0.77 | EPHX2 (0.46) | TSHREPHX2P2RX7LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | TSHR 98/4885EPHX2 2573/4885P2RX7 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.